Carbamazepine Maintenance Treatment in Outpatient Schizophrenics

William T. Carpenter, Rose Kurz, Brian Kirkpatrick, Thomas E. Hanlon, Ann T. Summerfelt, Robert W. Buchanan, Royce W. Waltrip, Alan Breier

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

A double-blind crossover trial was used to evaluate Carbamazepine as the sole maintenance treatment of chronic, nonmanic schizophrenic outpatients whose conditions had been stabilized with the use of neuroleptics prior to study. Criteria of treatment effectiveness included the number of patients relapsing and time to relapse over a 95-day neuroleptic-free period during which either carbamazepine or placebo was administered. Relapse was determined by the concordance of psychiatric ratings and independent clinical judgments indicating significant worsening. Results for 27 patients (13 receiving carbamazepine and 14 receiving placebo) involved in the first phase of this treatment comparison were nondifferentiating. Corroborating descriptive findings in the second phase were available for 14 of these patients. There was no evidence supporting the existence of a treatment-relevant subgroup defined by eqisodic dyscontrol phenomena.

Original languageEnglish (US)
Pages (from-to)69-72
Number of pages4
JournalArchives of General Psychiatry
Volume48
Issue number1
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Carbamazepine
Outpatients
Antipsychotic Agents
Placebos
Recurrence
Cross-Over Studies
Psychiatry
Therapeutics
Placebo
Relapse

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Carpenter, W. T., Kurz, R., Kirkpatrick, B., Hanlon, T. E., Summerfelt, A. T., Buchanan, R. W., ... Breier, A. (1991). Carbamazepine Maintenance Treatment in Outpatient Schizophrenics. Archives of General Psychiatry, 48(1), 69-72. https://doi.org/10.1001/archpsyc.1991.01810250071010

Carbamazepine Maintenance Treatment in Outpatient Schizophrenics. / Carpenter, William T.; Kurz, Rose; Kirkpatrick, Brian; Hanlon, Thomas E.; Summerfelt, Ann T.; Buchanan, Robert W.; Waltrip, Royce W.; Breier, Alan.

In: Archives of General Psychiatry, Vol. 48, No. 1, 1991, p. 69-72.

Research output: Contribution to journalArticle

Carpenter, WT, Kurz, R, Kirkpatrick, B, Hanlon, TE, Summerfelt, AT, Buchanan, RW, Waltrip, RW & Breier, A 1991, 'Carbamazepine Maintenance Treatment in Outpatient Schizophrenics', Archives of General Psychiatry, vol. 48, no. 1, pp. 69-72. https://doi.org/10.1001/archpsyc.1991.01810250071010
Carpenter WT, Kurz R, Kirkpatrick B, Hanlon TE, Summerfelt AT, Buchanan RW et al. Carbamazepine Maintenance Treatment in Outpatient Schizophrenics. Archives of General Psychiatry. 1991;48(1):69-72. https://doi.org/10.1001/archpsyc.1991.01810250071010
Carpenter, William T. ; Kurz, Rose ; Kirkpatrick, Brian ; Hanlon, Thomas E. ; Summerfelt, Ann T. ; Buchanan, Robert W. ; Waltrip, Royce W. ; Breier, Alan. / Carbamazepine Maintenance Treatment in Outpatient Schizophrenics. In: Archives of General Psychiatry. 1991 ; Vol. 48, No. 1. pp. 69-72.
@article{782ff6a6f12a413c92b8854a25e3d8f4,
title = "Carbamazepine Maintenance Treatment in Outpatient Schizophrenics",
abstract = "A double-blind crossover trial was used to evaluate Carbamazepine as the sole maintenance treatment of chronic, nonmanic schizophrenic outpatients whose conditions had been stabilized with the use of neuroleptics prior to study. Criteria of treatment effectiveness included the number of patients relapsing and time to relapse over a 95-day neuroleptic-free period during which either carbamazepine or placebo was administered. Relapse was determined by the concordance of psychiatric ratings and independent clinical judgments indicating significant worsening. Results for 27 patients (13 receiving carbamazepine and 14 receiving placebo) involved in the first phase of this treatment comparison were nondifferentiating. Corroborating descriptive findings in the second phase were available for 14 of these patients. There was no evidence supporting the existence of a treatment-relevant subgroup defined by eqisodic dyscontrol phenomena.",
author = "Carpenter, {William T.} and Rose Kurz and Brian Kirkpatrick and Hanlon, {Thomas E.} and Summerfelt, {Ann T.} and Buchanan, {Robert W.} and Waltrip, {Royce W.} and Alan Breier",
year = "1991",
doi = "10.1001/archpsyc.1991.01810250071010",
language = "English (US)",
volume = "48",
pages = "69--72",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Carbamazepine Maintenance Treatment in Outpatient Schizophrenics

AU - Carpenter, William T.

AU - Kurz, Rose

AU - Kirkpatrick, Brian

AU - Hanlon, Thomas E.

AU - Summerfelt, Ann T.

AU - Buchanan, Robert W.

AU - Waltrip, Royce W.

AU - Breier, Alan

PY - 1991

Y1 - 1991

N2 - A double-blind crossover trial was used to evaluate Carbamazepine as the sole maintenance treatment of chronic, nonmanic schizophrenic outpatients whose conditions had been stabilized with the use of neuroleptics prior to study. Criteria of treatment effectiveness included the number of patients relapsing and time to relapse over a 95-day neuroleptic-free period during which either carbamazepine or placebo was administered. Relapse was determined by the concordance of psychiatric ratings and independent clinical judgments indicating significant worsening. Results for 27 patients (13 receiving carbamazepine and 14 receiving placebo) involved in the first phase of this treatment comparison were nondifferentiating. Corroborating descriptive findings in the second phase were available for 14 of these patients. There was no evidence supporting the existence of a treatment-relevant subgroup defined by eqisodic dyscontrol phenomena.

AB - A double-blind crossover trial was used to evaluate Carbamazepine as the sole maintenance treatment of chronic, nonmanic schizophrenic outpatients whose conditions had been stabilized with the use of neuroleptics prior to study. Criteria of treatment effectiveness included the number of patients relapsing and time to relapse over a 95-day neuroleptic-free period during which either carbamazepine or placebo was administered. Relapse was determined by the concordance of psychiatric ratings and independent clinical judgments indicating significant worsening. Results for 27 patients (13 receiving carbamazepine and 14 receiving placebo) involved in the first phase of this treatment comparison were nondifferentiating. Corroborating descriptive findings in the second phase were available for 14 of these patients. There was no evidence supporting the existence of a treatment-relevant subgroup defined by eqisodic dyscontrol phenomena.

UR - http://www.scopus.com/inward/record.url?scp=0026099291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026099291&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1991.01810250071010

DO - 10.1001/archpsyc.1991.01810250071010

M3 - Article

VL - 48

SP - 69

EP - 72

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 1

ER -